{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:17:47Z","timestamp":1792113467285,"version":"4.4.0"},"reference-count":222,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["NCT02906020"],"award-info":[{"award-number":["NCT02906020"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.addr.2022.114402","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T19:07:55Z","timestamp":1656184075000},"page":"114402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease"],"prefix":"10.1016","volume":"187","author":[{"given":"Mia","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Revel-Vilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114402_b0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jmcb\/mjt022","article-title":"The lysosome: From waste bag to potential therapeutic target","volume":"5","author":"Appelqvist","year":"2013","journal-title":"J. Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2022.114402_b0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","article-title":"Lysosomes as dynamic regulators of cell and organismal homeostasis","volume":"21","author":"Ballabio","year":"2020","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2022.114402_b0015","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/ATVBAHA.119.312136","article-title":"Lysosomal acid lipase in lipid metabolism and beyond","volume":"39","author":"Li","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2022.114402_b0020","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/cells10112965","article-title":"The unfolded protein response as a guardian of the secretory pathway","volume":"10","author":"Radanovic","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.addr.2022.114402_b0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2017.09.023","article-title":"Guardians of the erad galaxy","volume":"171","author":"Sun","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114402_b0030","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.1038\/s41598-019-47607-5","article-title":"Endoplasmic reticulum stress disrupts lysosomal homeostasis and induces blockade of autophagic flux in human trophoblasts","volume":"9","author":"Nakashima","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114402_b0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant alpha-galactosidase a in an endogenous enzyme deficient background: A biochemical animal model for studying active-site specific chaperone therapy for fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2022.114402_b0040","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of n370s beta -glucosidase: A therapeutic strategy for gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b0045","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"Er retention and degradation as the molecular basis underlying gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0050","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/hmg\/ddh264","article-title":"Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase i to lysosomes","volume":"13","author":"Steinfeld","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0055","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/glycob\/cwp183","article-title":"A sensitive fluorescence-based assay for monitoring gm2 ganglioside hydrolysis in live patient cells and their lysates","volume":"20","author":"Tropak","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2022.114402_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060026","article-title":"Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis","volume":"6","author":"Mu","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.addr.2022.114402_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007434","article-title":"Protein misfolding as an underlying molecular defect in mucopolysaccharidosis iii type c","volume":"4","author":"Feldhammer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2022.114402_b0070","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes as a therapeutic target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.addr.2022.114402_b0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2022.114402_b0080","first-page":"472","article-title":"Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 gaucher disease","volume":"11","author":"Pastores","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2022.114402_b0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2010.10.009","article-title":"Improving the accuracy of mri spleen and liver volume measurements: A phase iii gaucher disease clinical trial setting as a model","volume":"46","author":"Bracoud","year":"2011","journal-title":"Blood. Cells. Mol. Dis."},{"key":"10.1016\/j.addr.2022.114402_b0090","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2022.114402_b0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: Lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.addr.2022.114402_b0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0065-2660(08)60202-3","article-title":"Gaucher disease","volume":"32","author":"Beutler","year":"1995","journal-title":"Adv. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0105","first-page":"309","article-title":"The enzymatic defect in gaucher disease","volume":"95","author":"Brady","year":"1982","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.addr.2022.114402_b0110","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2022.114402_b0115","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and parkinson's disease in ashkenazi jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114402_b0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.WNL.0000072482.70963.D7","article-title":"Gaucher's. disease. with. parkinson's. disease:. Clinical. and. pathological. aspects","volume":"61","author":"Bembi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2022.114402_b0125","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of parkinson's syndrome in type i gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.addr.2022.114402_b0130","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114402_b0135","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2022.114402_b0140","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009399","article-title":"Alpha-synuclein in parkinson's disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"key":"10.1016\/j.addr.2022.114402_b0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"Gba-associated parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0150","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of gba mutations and the e326k polymorphism with motor and cognitive progression in parkinson disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.addr.2022.114402_b0155","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","article-title":"Genotype-phenotype correlations between gba mutations and parkinson disease risk and onset","volume":"70","author":"Gan-Or","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2022.114402_b0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.12.014","article-title":"A \u201cdose\u201d effect of mutations in the gba gene on parkinson's disease phenotype","volume":"36","author":"Thaler","year":"2017","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0165","first-page":"921","article-title":"Prevalence of nine mutations among jewish and non-jewish gaucher disease patients","volume":"53","author":"Horowitz","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0170","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0006-291X(73)90916-9","article-title":"Deficiency of glucosylsphingosine: Beta-glucosidase in gaucher disease","volume":"54","author":"Raghavan","year":"1973","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2022.114402_b0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1432-1033.1985.tb08655.x","article-title":"Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase","volume":"146","author":"Vaccaro","year":"1985","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.addr.2022.114402_b0180","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1172\/JCI110363","article-title":"Selective effects of glucocerebroside (gaucher's storage material) on macrophage cultures","volume":"68","author":"Gery","year":"1981","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2022.114402_b0185","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/BF02388464","article-title":"A biochemical and immunocytochemical study on the targeting of alglucerase in murine liver","volume":"27","author":"Willemsen","year":"1995","journal-title":"Histochem. J."},{"key":"10.1016\/j.addr.2022.114402_b0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fphys.2014.00009","article-title":"Of macrophages and red blood cells; a complex love story","volume":"5","author":"de Back","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2022.114402_b0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1203\/00006450-200008000-00018","article-title":"Glucosylsphingosine accumulation in mice and patients with type 2 gaucher disease begins early in gestation","volume":"48","author":"Orvisky","year":"2000","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2022.114402_b0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S","article-title":"Glucocerebrosidase gene mutations in patients with type 2 gaucher disease","volume":"15","author":"Stone","year":"2000","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.addr.2022.114402_b0205","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1203\/00006450-199805000-00003","article-title":"Genotypic heterogeneity and phenotypic variation among patients with type 2 gaucher's disease","volume":"43","author":"Tayebi","year":"1998","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2022.114402_b0210","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jimd.12235","article-title":"The definition of neuronopathic gaucher disease","volume":"43","author":"Schiffmann","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114402_b0215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: Immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114402_b0220","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/17474086.2021.1908120","article-title":"Hematological manifestations and complications of gaucher disease","volume":"14","author":"Revel-Vilk","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.addr.2022.114402_b0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/ijms18010112","article-title":"Osteocyte alterations induce osteoclastogenesis in an in vitro model of gaucher disease","volume":"18","author":"Bondar","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114402_b0230","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2020.07.003","article-title":"Corrigendum to \u201cgaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis\u201d [molecular genetics metabolism 130 (2020) 274\u2013282]","volume":"131","author":"Crivaro","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114402_b0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2013.04.006","article-title":"Enhanced differentiation of osteoclasts from mononuclear precursors in patients with gaucher disease","volume":"51","author":"Reed","year":"2013","journal-title":"Blood. Cells. Mol. Dis."},{"key":"10.1016\/j.addr.2022.114402_b0240","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: From pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.addr.2022.114402_b0245","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.gene.2013.09.072","article-title":"Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of gaucher disease","volume":"532","author":"Mucci","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.addr.2022.114402_b0250","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/jcm10102217","article-title":"Trap5b and rankl\/opg predict bone pathology in patients with gaucher disease","volume":"10","author":"Ivanova","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2022.114402_b0255","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0378-1119(90)90264-R","article-title":"Prevalent and rare mutations among gaucher patients","volume":"96","author":"Eyal","year":"1990","journal-title":"Gene"},{"key":"10.1016\/j.addr.2022.114402_b0260","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.addr.2022.114402_b0265","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.85.7.2349","article-title":"Genetic heterogeneity in type 1 gaucher disease: Multiple genotypes in ashkenazic and non-ashkenazic individuals","volume":"85","author":"Tsuji","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b0270","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM198703053161002","article-title":"A mutation in the human glucocerebrosidase gene in neuronopathic gaucher's disease","volume":"316","author":"Tsuji","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114402_b0275","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in gaucher disease implicate the role of modifiers","volume":"42","author":"Goker-Alpan","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0280","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/mgme.1998.2675","article-title":"Type 2 gaucher disease with hydrops fetalis in an ashkenazi jewish family resulting from a novel recombinant allele and a rare splice junction mutation in the glucocerebrosidase locus","volume":"63","author":"Reissner","year":"1998","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114402_b0285","doi-asserted-by":"crossref","first-page":"e2119","DOI":"10.1212\/WNL.0000000000010605","article-title":"The natural history of type 2 gaucher disease in the 21st century: A retrospective study","volume":"95","author":"Roshan Lal","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2022.114402_b0290","doi-asserted-by":"crossref","first-page":"F163","DOI":"10.1136\/fn.82.2.F163","article-title":"Type 2 gaucher disease: The collodion baby phenotype revisited","volume":"82","author":"Stone","year":"2000","journal-title":"Arch. Dis. Child. Fetal. Neonatal. Ed."},{"key":"10.1016\/j.addr.2022.114402_b0295","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1006\/geno.1993.1035","article-title":"Identification of six new gaucher disease mutations","volume":"15","author":"Beutler","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/j.addr.2022.114402_b0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0888-7543(89)90319-4","article-title":"The human glucocerebrosidase gene and pseudogene: Structure and evolution","volume":"4","author":"Horowitz","year":"1989","journal-title":"Genomics"},{"key":"10.1016\/j.addr.2022.114402_b0305","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/BF00200914","article-title":"Three unique base pair changes in a family with gaucher disease","volume":"87","author":"Eyal","year":"1991","journal-title":"Hum. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0310","first-page":"179","article-title":"Gaucher disease: Four families with previously undescribed mutations","volume":"108","author":"Beutler","year":"1996","journal-title":"Proc. Assoc. Am. Phys."},{"key":"10.1016\/j.addr.2022.114402_b0315","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ymgme.2019.10.001","article-title":"Revisiting the non-gaucher-gba-e326k carrier state: Is it sufficient to increase parkinson's disease risk?","volume":"128","author":"Goldstein","year":"2019","journal-title":"Mol. Genet. Metab"},{"key":"10.1016\/j.addr.2022.114402_b0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcmd.2005.03.006","article-title":"Use of fluorescent substrates for characterization of gaucher disease mutations","volume":"35","author":"Ron","year":"2005","journal-title":"Blood. Cells. Mol. Dis."},{"key":"10.1016\/j.addr.2022.114402_b0325","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20043","article-title":"Functional analysis of 13 gba mutant alleles identified in gaucher disease patients: Pathogenic changes and \u201cmodifier\u201d polymorphisms","volume":"23","author":"Montfort","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.addr.2022.114402_b0330","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/mds.28112","article-title":"A large-scale full gba1 gene screening in parkinson's disease in the netherlands","volume":"35","author":"den Heijer","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0335","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0005-2736(86)90387-1","article-title":"Comparison of the properties of a soluble form of glucocerebrosidase from human urine with those of the membrane-associated tissue enzyme","volume":"863","author":"Aerts","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2022.114402_b0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF00314009","article-title":"Ultrastructural localization of glucocerebrosidase in cultured gaucher's disease fibroblasts by immunocytochemistry","volume":"234","author":"Willemsen","year":"1987","journal-title":"J. Neurol."},{"key":"10.1016\/j.addr.2022.114402_b0345","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0304-4165(88)90030-X","article-title":"Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation","volume":"964","author":"Aerts","year":"1988","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2022.114402_b0350","first-page":"179","article-title":"The subcellular localization of soluble and membrane-bound lysosomal enzymes in i-cell fibroblasts: A comparative immunocytochemical study","volume":"39","author":"van Dongen","year":"1985","journal-title":"Eur. J. Cell. Biol."},{"key":"10.1016\/j.addr.2022.114402_b0355","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/tra.12313","article-title":"Mannose 6-phosphate-independent lysosomal sorting of limp-2","volume":"16","author":"Blanz","year":"2015","journal-title":"Traffic"},{"key":"10.1016\/j.addr.2022.114402_b0360","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"Limp-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114402_b0365","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1093\/hmg\/ddn124","article-title":"A nonsense mutation in the limp-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome","volume":"17","author":"Balreira","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0370","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ajhg.2007.12.019","article-title":"Array-based gene discovery with three unrelated subjects shows scarb2\/limp-2 deficiency causes myoclonus epilepsy and glomerulosclerosis","volume":"82","author":"Berkovic","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0375","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1096\/fj.15-271148","article-title":"Role of limp-2 in the intracellular trafficking of beta-glucosidase in different human cellular models","volume":"29","author":"Malini","year":"2015","journal-title":"FASEB. J"},{"key":"10.1016\/j.addr.2022.114402_b0380","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0005-2760(81)90134-X","article-title":"Mechanism of activation of glucocerebrosidase by co-beta-glucosidase (glucosidase activator protein)","volume":"664","author":"Berent","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2022.114402_b0385","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.2842863","article-title":"Coding of two sphingolipid activator proteins (sap-1 and sap-2) by same genetic locus","volume":"241","author":"O'Brien","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114402_b0390","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0888-7543(89)90014-1","article-title":"Molecular cloning of a human co-beta-glucosidase cdna: Evidence that four sphingolipid hydrolase activator proteins are encoded by single genes in humans and rats","volume":"5","author":"Rorman","year":"1989","journal-title":"Genomics"},{"key":"10.1016\/j.addr.2022.114402_b0395","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1242\/jcs.067686","article-title":"Golgi-to-phagosome transport of acid sphingomyelinase and prosaposin is mediated by sortilin","volume":"123","author":"Wahe","year":"2010","journal-title":"J. Cell. Sci"},{"key":"10.1016\/j.addr.2022.114402_b0400","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1098\/rstb.2003.1265","article-title":"Biosynthesis and degradation of mammalian glycosphingolipids","volume":"358","author":"Sandhoff","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"10.1016\/j.addr.2022.114402_b0405","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/hmg\/10.11.1191","article-title":"A mutation in the saposin a domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse","volume":"10","author":"Matsuda","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2019.08.001","article-title":"Rare saposin a deficiency: Novel variant and psychosine analysis","volume":"129","author":"Calderwood","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114402_b0415","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/BF00711364","article-title":"Molecular genetics of metachromatic leukodystrophy","volume":"17","author":"Gieselmann","year":"1994","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114402_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01233949","article-title":"Mutational analysis in a patient with a variant form of gaucher disease caused by sap-2 deficiency","volume":"19","author":"Rafi","year":"1993","journal-title":"Somat. Cell. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0425","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0014-5793(91)80760-Z","article-title":"Mutation in the sphingolipid activator protein 2 in a patient with a variant of gaucher disease","volume":"284","author":"Schnabel","year":"1991","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2022.114402_b0430","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1006\/bbrc.1994.1612","article-title":"Sphingolipid activator protein d (sap-d) stimulates the lysosomal degradation of ceramide in vivo","volume":"200","author":"Klein","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2022.114402_b0435","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1093\/hmg\/ddh281","article-title":"Mutation in saposin d domain of sphingolipid activator protein gene causes urinary system defects and cerebellar purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse","volume":"13","author":"Matsuda","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0440","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/abbi.1997.9958","article-title":"Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): Its mechanism and inhibition by ganglioside","volume":"341","author":"Hiraiwa","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.addr.2022.114402_b0445","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/BF01716064","article-title":"Activator protein deficient gaucher's. A second patient with the newly identified lipid storage disorder","volume":"67","author":"Christomanou","year":"1989","journal-title":"Klin. Wochenschr"},{"key":"10.1016\/j.addr.2022.114402_b0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004010050960","article-title":"Neuronopathic juvenile glucosylceramidosis due to sap-c deficiency: Clinical course, neuropathology and brain lipid composition in this gaucher disease variant","volume":"97","author":"Pampols","year":"1999","journal-title":"Acta. Neuropathol."},{"key":"10.1016\/j.addr.2022.114402_b0455","unstructured":"A. Radha Rama Devi, S. Kadali, A. Radhika, V. Singh, M.A. Kumar, G.M. Reddy, S.M. Naushad, Acute gaucher disease-like condition in an indian infant with a novel biallelic mutation in the prosaposin gene, J. Pediatr. Genet., 8 (2019) 81-85."},{"key":"10.1016\/j.addr.2022.114402_b0460","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1399-0004.2007.00899.x","article-title":"Non-neuronopathic gaucher disease due to saposin c deficiency","volume":"72","author":"Tylki-Szymanska","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0465","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ymgme.2011.09.010","article-title":"Gaucher disease due to saposin c deficiency, previously described as non-neuronopathic form\u2013no positive effects after 2-years of miglustat therapy","volume":"104","author":"Tylki-Szymanska","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114402_b0470","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2017.03.005","article-title":"Hspa5 gene encoding hsp70 chaperone bip in the endoplasmic reticulum","volume":"618","author":"Wang","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.addr.2022.114402_b0475","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1074\/jbc.REV118.002804","article-title":"The endoplasmic reticulum (er) chaperone bip is a master regulator of er functions: Getting by with a little help from erdj friends","volume":"294","author":"Pobre","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2022.114402_b0480","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cell.2012.11.012","article-title":"Cleaning up: Er-associated degradation to the rescue","volume":"151","author":"Brodsky","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114402_b0485","first-page":"17","article-title":"Recognition and delivery of erad substrates to the proteasome and alternative paths for cell survival","volume":"300","author":"McCracken","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.addr.2022.114402_b0490","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1600-0854.2008.00729.x","article-title":"The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum","volume":"9","author":"Nakatsukasa","year":"2008","journal-title":"Traffic"},{"key":"10.1016\/j.addr.2022.114402_b0495","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1742-4658.2007.05639.x","article-title":"Er stress and diseases","volume":"274","author":"Yoshida","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.addr.2022.114402_b0500","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.addr.2022.114402_b0505","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/hmg\/ddq292","article-title":"Interaction between parkin and mutant glucocerebrosidase variants: A possible link between parkinson disease and gaucher disease","volume":"19","author":"Ron","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0510","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/hmg\/dds535","article-title":"Itch regulates degradation of mutant glucocerebrosidase: Implications to gaucher disease","volume":"22","author":"Maor","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0515","doi-asserted-by":"crossref","first-page":"21665","DOI":"10.1073\/pnas.1014376107","article-title":"Decreased glucocerebrosidase activity in gaucher disease parallels quantitative enzyme loss due to abnormal interaction with tcp1 and c-cbl","volume":"107","author":"Lu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b0520","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1385\/MB:34:2:279","article-title":"The unfolded protein response","volume":"34","author":"Schroder","year":"2006","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.addr.2022.114402_b0525","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm2199","article-title":"Signal integration in the endoplasmic reticulum unfolded protein response","volume":"8","author":"Ron","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"Suppl 2","key":"10.1016\/j.addr.2022.114402_b0530","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1463-1326.2010.01281.x","article-title":"The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in beta-cells","volume":"12","author":"Kaufman","year":"2010","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.addr.2022.114402_b0535","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033894","article-title":"Early events in the endoplasmic reticulum unfolded protein response","volume":"11","author":"Preissler","year":"2019","journal-title":"Cold. Spring. Harb. Perspect. Biol."},{"key":"10.1016\/j.addr.2022.114402_b0540","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fphys.2012.00263","article-title":"The endoplasmic reticulum stress response in aging and age-related diseases","volume":"3","author":"Brown","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2022.114402_b0545","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1051\/medsci\/2007233291","article-title":"unfolded protein response: Its role in physiology and physiopathology","volume":"23","author":"Foufelle","year":"2007","journal-title":"Med. Sci. (Paris)"},{"key":"10.1016\/j.addr.2022.114402_b0550","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: From stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114402_b0555","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.31","article-title":"Induction of er stress in response to oxygen-glucose deprivation of cortical cultures involves the activation of the perk and ire-1 pathways and of caspase-12","volume":"2","author":"Badiola","year":"2011","journal-title":"Cell. Death. Dis."},{"key":"10.1016\/j.addr.2022.114402_b0560","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1515\/bchm2.1968.349.1.767","article-title":"investigations on the mechanism of action of glycoside-splitting enzymes. 3. Labelling of the active center of a beta-glucosidase from aspergillus wentii with (14c) conduritol b epoxide","volume":"349","author":"Legler","year":"1968","journal-title":"Hoppe. Seylers. Z. Physiol. Chem."},{"key":"10.1016\/j.addr.2022.114402_b0565","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b0570","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/hmg\/ddp061","article-title":"No evidence for activation of the unfolded protein response in neuronopathic models of gaucher disease","volume":"18","author":"Farfel-Becker","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0575","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"Mds research criteria for prodromal parkinson's disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0580","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cca.2015.04.042","article-title":"Candidate genes for parkinson disease: Lessons from pathogenesis","volume":"449","author":"De Rosa","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.addr.2022.114402_b0585","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","article-title":"Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed parkinson's disease: A longitudinal cohort study and validation","volume":"16","author":"Latourelle","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.addr.2022.114402_b0590","doi-asserted-by":"crossref","unstructured":"M.A. Nalls, C. Blauwendraat, C.L. Vallerga, K. Heilbron, S. Bandres-Ciga, D. Chang, M. Tan, D.A. Kia, A.J. Noyce, A. Xue, J. Bras, E. Young, R. von Coelln, J. Simon-Sanchez, C. Schulte, M. Sharma, L. Krohn, L. Pihlstrom, A. Siitonen, H. Iwaki, H. Leonard, F. Faghri, J.R. Gibbs, D.G. Hernandez, S.W. Scholz, J.A. Botia, M. Martinez, J.C. Corvol, S. Lesage, J. Jankovic, L.M. Shulman, M. Sutherland, P. Tienari, K. Majamaa, M. Toft, O.A. Andreassen, T. Bangale, A. Brice, J. Yang, Z. Gan-Or, T. Gasser, P. Heutink, J.M. Shulman, N.W. Wood, D.A. Hinds, J.A. Hardy, H.R. Morris, J. Gratten, P.M. Visscher, R.R. Graham, A.B. Singleton, T. andMe Research, C. System Genomics of Parkinson's Disease, C. International Parkinson's Disease Genomics, Identification of novel risk loci, causal insights, and heritable risk for parkinson's disease: A meta-analysis of genome-wide association studies, Lancet Neurol., 18 (2019) 1091-1102.","DOI":"10.1016\/S1474-4422(19)30320-5"},{"issue":"Suppl","key":"10.1016\/j.addr.2022.114402_b0595","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/nm1067","article-title":"Molecular pathways to neurodegeneration","volume":"10","author":"Bossy-Wetzel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2022.114402_b0600","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","article-title":"Understanding dopaminergic cell death pathways in parkinson disease","volume":"90","author":"Michel","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.addr.2022.114402_b0605","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13024-020-00408-1","article-title":"Glycosphingolipids and neuroinflammation in parkinson's disease","volume":"15","author":"Belarbi","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.addr.2022.114402_b0610","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11c](r)-pk11195 pet in idiopathic parkinson's disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2022.114402_b0615","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature09615","article-title":"The myeloid cells of the central nervous system parenchyma","volume":"468","author":"Ransohoff","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114402_b0620","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0625","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mdc3.12481","article-title":"Frequency of gba variants in autopsy-proven multiple system atrophy","volume":"4","author":"Sklerov","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.addr.2022.114402_b0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/nmt.15.68","article-title":"Clinical studies of gba1-associated parkinsonism: Progress and challenges","volume":"6","author":"Lopez","year":"2016","journal-title":"Neurodegener Dis. Manag."},{"key":"10.1016\/j.addr.2022.114402_b0635","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild gba mutations on parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2022.114402_b0640","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","article-title":"Selective loss of glucocerebrosidase activity in sporadic parkinson's disease and dementia with lewy bodies","volume":"10","author":"Chiasserini","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.addr.2022.114402_b0645","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.addr.2022.114402_b0650","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.4161\/auto.29074","article-title":"Glucocerebrosidase deficits in sporadic parkinson disease","volume":"10","author":"Murphy","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.addr.2022.114402_b0655","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acn3.177","article-title":"Progressive decline of glucocerebrosidase in aging and parkinson's disease","volume":"2","author":"Rocha","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.addr.2022.114402_b0660","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/cells8010065","article-title":"Oxidative insults and mitochondrial DNA mutation promote enhanced autophagy and mitophagy compromising cell viability in pluripotent cell model of mitochondrial disease","volume":"8","author":"Lin","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.addr.2022.114402_b0665","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/mds.25135","article-title":"Living on the edge with too many mouths to feed: Why dopamine neurons die","volume":"27","author":"Bolam","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0670","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1016\/j.febslet.2015.10.021","article-title":"Understanding the susceptibility of dopamine neurons to mitochondrial stressors in parkinson's disease","volume":"589","author":"Haddad","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2022.114402_b0675","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tins.2014.12.009","article-title":"Impaired intracellular trafficking defines early parkinson's disease","volume":"38","author":"Hunn","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.addr.2022.114402_b0680","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.26359","article-title":"Gba variants are associated with a distinct pattern of cognitive deficits in parkinson's disease","volume":"31","author":"Mata","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0685","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.parkreldis.2020.09.036","article-title":"A rapid and low-cost test for screening the most common parkinson's disease-related gba variants","volume":"80","author":"Straniero","year":"2020","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0690","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the gaucher's disease-related glucocerebrosidase gene in europeans with parkinson's disease","volume":"20","author":"Lesage","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0695","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.parkreldis.2019.01.030","article-title":"The distribution and risk effect of gba variants in a large cohort of pd patients from colombia and peru","volume":"63","author":"Velez-Pardo","year":"2019","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0700","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jalz.2018.04.006","article-title":"Association of glucocerebrosidase polymorphisms and mutations with dementia in incident parkinson's disease","volume":"14","author":"Lunde","year":"2018","journal-title":"Alzheimers. Dement"},{"key":"10.1016\/j.addr.2022.114402_b0705","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jnnp-2017-317348","article-title":"P.R.c. consortium, Features of gba-associated parkinson's disease at presentation in the uk tracking parkinson's study","volume":"89","author":"Malek","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.addr.2022.114402_b0710","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/00207454.2015.1023436","article-title":"Mutations in the glucocerebrosidase gene are common in patients with parkinson's disease from eastern canada","volume":"126","author":"Han","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.addr.2022.114402_b0715","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.parkreldis.2019.11.022","article-title":"Nanopore sequencing of the glucocerebrosidase (gba) gene in a new zealand parkinson's disease cohort","volume":"70","author":"Graham","year":"2020","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0720","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.neurobiolaging.2007.11.016","article-title":"Complete screening for glucocerebrosidase mutations in parkinson disease patients from portugal","volume":"30","author":"Bras","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.addr.2022.114402_b0725","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2009.01.029","article-title":"Complete screening for glucocerebrosidase mutations in parkinson disease patients from greece","volume":"452","author":"Kalinderi","year":"2009","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.addr.2022.114402_b0730","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neulet.2016.07.008","article-title":"Mutations in glucocerebrosidase are a major genetic risk factor for parkinson's disease and increase susceptibility to dementia in a flanders-belgian cohort","volume":"629","author":"Crosiers","year":"2016","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.addr.2022.114402_b0735","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/WNL.0b013e318207b01e","article-title":"Mutations in the glucocerebrosidase gene confer a risk for parkinson disease in north africa","volume":"76","author":"Lesage","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2022.114402_b0740","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neulet.2012.02.035","article-title":"Association of mutations in the glucocerebrosidase gene with parkinson disease in a korean population","volume":"514","author":"Choi","year":"2012","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.addr.2022.114402_b0745","doi-asserted-by":"crossref","unstructured":"A.K. Emelyanov, T.S. Usenko, C. Tesson, K.A. Senkevich, M.A. Nikolaev, I.V. Miliukhina, A.E. Kopytova, A.A. Timofeeva, A.F. Yakimovsky, S. Lesage, A. Brice, S.N. Pchelina, Mutation analysis of parkinson's disease genes in a russian data set, Neurobiol. Aging, 71 (2018) 267 e267-267 e210.","DOI":"10.1016\/j.neurobiolaging.2018.06.027"},{"key":"10.1016\/j.addr.2022.114402_b0750","doi-asserted-by":"crossref","unstructured":"C. Ran, L. Brodin, L. Forsgren, M. Westerlund, M. Ramezani, S. Gellhaar, F. Xiang, C. Fardell, H. Nissbrandt, P. Soderkvist, A. Puschmann, E. Ygland, L. Olson, T. Willows, A. Johansson, O. Sydow, K. Wirdefeldt, D. Galter, P. Svenningsson, A.C. Belin, Strong association between glucocerebrosidase mutations and parkinson's disease in sweden, Neurobiol. Aging, 45 (2016) 212 e215-212 e211.","DOI":"10.1016\/j.neurobiolaging.2016.04.022"},{"key":"10.1016\/j.addr.2022.114402_b0755","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archneurol.2009.72","article-title":"Mutations for gaucher disease confer high susceptibility to parkinson disease","volume":"66","author":"Mitsui","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.addr.2022.114402_b0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167749","article-title":"Gba variants influence motor and non-motor features of parkinson's disease","volume":"11","author":"Jesus","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2022.114402_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135816","article-title":"Identification of gba mutations among neurodegenerative disease patients from eastern india","volume":"751","author":"Biswas","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.addr.2022.114402_b0770","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.parkreldis.2020.07.014","article-title":"Novel and reported variants in parkinson's disease genes confer high disease burden among indians","volume":"78","author":"Kumar","year":"2020","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0775","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/jnnp.2006.105940","article-title":"Glucocerebrosidase gene mutation is a risk factor for early onset of parkinson disease among taiwanese","volume":"78","author":"Wu","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.addr.2022.114402_b0780","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.parkreldis.2011.11.028","article-title":"Glucocerebrosidase n370s and l444p mutations as risk factors for parkinson's disease in brazilian patients","volume":"18","author":"Guimaraes Bde","year":"2012","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0785","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.3390\/cells9112495","article-title":"The endoplasmic reticulum stress\/unfolded protein response and their contributions to parkinson's disease physiopathology","volume":"9","author":"Costa","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.addr.2022.114402_b0790","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1523\/JNEUROSCI.22-24-10690.2002","article-title":"Endoplasmic reticulum stress and the unfolded protein response in cellular models of parkinson's disease","volume":"22","author":"Ryu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2022.114402_b0795","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0166-2236(03)00197-8","article-title":"'Unfolding' pathways in neurodegenerative disease","volume":"26","author":"Forman","year":"2003","journal-title":"Trends. Neurosci."},{"key":"10.1016\/j.addr.2022.114402_b0800","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.molmed.2012.12.005","article-title":"An ercentric view of parkinson's disease","volume":"19","author":"Mercado","year":"2013","journal-title":"Trends. Mol. Med."},{"key":"10.1016\/j.addr.2022.114402_b0805","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.1245296","article-title":"Identification and rescue of alpha-synuclein toxicity in parkinson patient-derived neurons","volume":"342","author":"Chung","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114402_b0810","first-page":"333","article-title":"Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of lewy bodies","volume":"28","author":"Slodzinski","year":"2009","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.addr.2022.114402_b0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55782\/ane-2015-2012","article-title":"Role of the unfolded protein response in the pathogenesis of parkinson's disease","volume":"75","author":"Varma","year":"2015","journal-title":"Acta. Neurobiol. Exp. (Wars)"},{"key":"10.1016\/j.addr.2022.114402_b0820","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2007.01.043","article-title":"Activation of the unfolded protein response in parkinson's disease","volume":"354","author":"Hoozemans","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2022.114402_b0825","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/nan.12260","article-title":"Unfolded protein response is activated in lewy body dementias","volume":"42","author":"Baek","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.addr.2022.114402_b0830","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1093\/hmg\/ddx331","article-title":"Alpha-synuclein induces the unfolded protein response in parkinson's disease snca triplication ipsc-derived neurons","volume":"26","author":"Heman-Ackah","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0835","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.brainres.2004.07.026","article-title":"Identification of the protein disulfide isomerase family member pdip in experimental parkinson's disease and lewy body pathology","volume":"1022","author":"Conn","year":"2004","journal-title":"Brain. Res."},{"key":"10.1016\/j.addr.2022.114402_b0840","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux","year":"1988","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2022.114402_b0845","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes snare-complex assembly in vivo and in vitro","volume":"329","author":"Burre","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114402_b0850","doi-asserted-by":"crossref","first-page":"29542","DOI":"10.1074\/jbc.M115.691592","article-title":"Dopamine transporter activity is modulated by alpha-synuclein","volume":"290","author":"Butler","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2022.114402_b0855","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114402_b0860","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1073\/pnas.0509567103","article-title":"Lewy bodies","volume":"103","author":"Shults","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b0865","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jnc.14704","article-title":"How is alpha-synuclein cleared from the cell?","volume":"150","author":"Stefanis","year":"2019","journal-title":"J. Neurochem"},{"key":"10.1016\/j.addr.2022.114402_b0870","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jmb.2006.12.044","article-title":"Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity","volume":"366","author":"Volles","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.addr.2022.114402_b0875","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.290.5493.985","article-title":"Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions","volume":"290","author":"Giasson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114402_b0880","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"Alpha-synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell. Biol."},{"key":"10.1016\/j.addr.2022.114402_b0885","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114402_b0890","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter alpha-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.addr.2022.114402_b0895","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1093\/brain\/awu291","article-title":"Augmentation of phenotype in a transgenic parkinson mouse heterozygous for a gaucher mutation","volume":"137","author":"Fishbein","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.addr.2022.114402_b0900","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/hmg\/ddz005","article-title":"The effect of mutant gba1 on accumulation and aggregation of alpha-synuclein","volume":"28","author":"Maor","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0905","doi-asserted-by":"crossref","first-page":"eabm6393","DOI":"10.1126\/sciadv.abm6393","article-title":"Mutant glucocerebrosidase impairs alpha-synuclein degradation by blockade of chaperone-mediated autophagy","volume":"8","author":"Kuo","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2022.114402_b0910","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","article-title":"Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction","volume":"111","author":"Ginns","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114402_b0915","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/ars.2015.6307","article-title":"Sustained systemic glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement c1q activation in mice","volume":"23","author":"Rocha","year":"2015","journal-title":"Antioxid. Redox. Signal."},{"key":"10.1016\/j.addr.2022.114402_b0920","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/mds.26278","article-title":"No evidence for substrate accumulation in parkinson brains with gba mutations","volume":"30","author":"Gegg","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0925","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1399-0004.1985.tb00229.x","article-title":"Glycosphingolipid studies of visceral tissues and brain from type 1 gaucher disease variants","volume":"27","author":"Nilsson","year":"1985","journal-title":"Clin. Genet."},{"key":"10.1016\/j.addr.2022.114402_b0930","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile gaucher disease","volume":"39","author":"Nilsson","year":"1982","journal-title":"J. Neurochem."},{"key":"10.1016\/j.addr.2022.114402_b0935","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","article-title":"Gba mutations, glucosylceramide and parkinson's disease","volume":"72","author":"Milenkovic","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.addr.2022.114402_b0940","first-page":"769","article-title":"A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for gaucher disease","volume":"9","author":"Westbroek","year":"2016","journal-title":"Dis. Model. Mech"},{"key":"10.1016\/j.addr.2022.114402_b0945","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"Cns expression of glucocerebrosidase corrects {alpha}-synuclein pathology and memory in a mouse model of gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b0950","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting cns glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b0955","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1523\/JNEUROSCI.20-16-06021.2000","article-title":"Neuropathology in mice expressing human alpha-synuclein","volume":"20","author":"van der Putten","year":"2000","journal-title":"J. Neurosci"},{"key":"10.1016\/j.addr.2022.114402_b0960","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.expneurol.2004.01.007","article-title":"Fibrillization of alpha-synuclein and tau in familial parkinson's disease caused by the a53t alpha-synuclein mutation","volume":"187","author":"Kotzbauer","year":"2004","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.addr.2022.114402_b0965","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"Ipsc-derived neurons from gba1-associated parkinson's disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Schondorf","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114402_b0970","doi-asserted-by":"crossref","first-page":"eaau6870","DOI":"10.1126\/scitranslmed.aau6870","article-title":"A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of parkinson\u2019s disease","volume":"11","author":"Burbulla","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2022.114402_b0975","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in ipsc-derived dopaminergic neurons from patients with gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2022.114402_b0980","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"Er stress and autophagic perturbations lead to elevated extracellular alpha-synuclein in gba-n370s parkinson's ipsc-derived dopamine neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem. Cell. Reports"},{"key":"10.1016\/j.addr.2022.114402_b0985","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002141","article-title":"Web-based genome-wide association study identifies two novel loci and a substantial genetic component for parkinson's disease","volume":"7","author":"Do","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.addr.2022.114402_b0990","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/mds.24886","article-title":"Evidence of an association between the scavenger receptor class b member 2 gene and parkinson's disease","volume":"27","author":"Michelakakis","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b0995","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2013.01.012","article-title":"Is parkinson disease associated with lysosomal integral membrane protein type-2?: Challenges in interpreting association data","volume":"108","author":"Maniwang","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114402_b1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135509","article-title":"Genetics variants and expression of the scarb2 gene in the pathogenesis of parkinson's disease in russia","volume":"741","author":"Usenko","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.addr.2022.114402_b1005","doi-asserted-by":"crossref","unstructured":"Y.L. Sosero, S. Bandres-Ciga, S. Hassin-Baer, R.N. Alcalay, Z. Gan-Or, C. International Parkinson's Disease Genomics, Lack of evidence for genetic association of saposins a, b, c and d with parkinson's disease, Brain, 143 (2020) e72.","DOI":"10.1093\/brain\/awaa214"},{"key":"10.1016\/j.addr.2022.114402_b1010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s12035-020-02218-4","article-title":"Genetic analysis of prosaposin, the lysosomal storage disorder gene in parkinson's disease","volume":"58","author":"Chen","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.addr.2022.114402_b1015","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in parkinson's disease with and without gba mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.addr.2022.114402_b1020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neulet.2017.08.040","article-title":"The gba variant e326k is associated with parkinson's disease and explains a genome-wide association signal","volume":"658","author":"Berge-Seidl","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.addr.2022.114402_b1025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.parkreldis.2009.05.008","article-title":"Mutations in the parkinson's disease genes, leucine rich repeat kinase 2 (lrrk2) and glucocerebrosidase (gba), are not associated with essential tremor","volume":"16","author":"Clark","year":"2010","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.addr.2022.114402_b1030","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2174\/1389203717666160311115956","article-title":"Involvement of gaucher disease mutations in parkinson disease","volume":"18","author":"Vilageliu","year":"2017","journal-title":"Curr. Protein. Pept. Sci"},{"key":"10.1016\/j.addr.2022.114402_b1035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mds.25248","article-title":"The glucocerobrosidase e326k variant predisposes to parkinson's disease, but does not cause gaucher's disease","volume":"28","author":"Duran","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2022.114402_b1040","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.biocel.2005.05.008","article-title":"Impaired trafficking of mutants of lysosomal glucocerebrosidase in gaucher's disease","volume":"37","author":"Schmitz","year":"2005","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"10.1016\/j.addr.2022.114402_b1045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1750-1172-9-86","article-title":"Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates paris and arts","volume":"9","author":"Bendikov-Bar","year":"2014","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.addr.2022.114402_b1050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038837","article-title":"Parkin promotes degradation of the mitochondrial pro-apoptotic arts protein","volume":"7","author":"Kemeny","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2022.114402_b1055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0092-8674(00)80611-X","article-title":"Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator pgc-1","volume":"98","author":"Wu","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114402_b1060","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"Paris (znf746) repression of pgc-1alpha contributes to neurodegeneration in parkinson's disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114402_b1065","first-page":"2712","article-title":"The contribution of mutant gba to the development of parkinson disease in drosophila","volume":"25","author":"Maor","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114402_b1070","doi-asserted-by":"crossref","first-page":"31380","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked gba mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114402_b1075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069147","article-title":"Expression of human gaucher disease gene gba generates neurodevelopmental defects and er stress in drosophila eye","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2022.114402_b1080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1750-1172-8-140","article-title":"Unfolded protein response in gaucher disease: From human to drosophila","volume":"8","author":"Maor","year":"2013","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.addr.2022.114402_b1085","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1073\/pnas.88.23.10544","article-title":"Identification of the second common jewish gaucher disease mutation makes possible population-based screening for the heterozygous state","volume":"88","author":"Beutler","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2022.114402_b1090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","article-title":"Mitochondrial dysfunction and mitophagy defect triggered by heterozygous gba mutations","volume":"15","author":"Li","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.addr.2022.114402_b1095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as novel therapeutics for diverse protein conformational diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol. Rev"},{"key":"10.1016\/j.addr.2022.114402_b1100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ebiom.2018.11.037","article-title":"The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase","volume":"38","author":"Fog","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2022.114402_b1105","doi-asserted-by":"crossref","first-page":"355ra118","DOI":"10.1126\/scitranslmed.aad9823","article-title":"Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses","volume":"8","author":"Kirkegaard","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2022.114402_b1110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: A nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA. Neurol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22002927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22002927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:35:23Z","timestamp":1759210523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22002927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":222,"alternative-id":["S0169409X22002927"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114402","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114402"}}